Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

667
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The extreme yet transient nature of glacial erosion.

Nature communications·2022
Same author

Prophylactic mesh augmentation using permanent synthetic mesh: outcomes of keyhole and Stapled Ostomy Reinforcement with Retromuscular Mesh techniques.

Hernia : the journal of hernias and abdominal wall surgery·2020
Same author

Computed tomography imaging in ventral hernia repair: can we predict the need for myofascial release?

Hernia : the journal of hernias and abdominal wall surgery·2020
Same author

Improving the rehabilitation of older people after emergency hospital admission.

Maturitas·2018
Same author

Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.

Clinical genetics·2017
Same author

Progranulin haploinsufficiency causes biphasic social dominance abnormalities in the tube test.

Genes, brain, and behavior·2016

相关实验视频

Updated: Sep 17, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

局部单剂量辐射改善了通过瘤透性淋巴细胞的采用细胞疗法.

Nina Obertopp1, Rebecca A Bekker2, G Daniel Grass3

  • 1Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida; Cancer Biology Ph.D. Program, University of South Florida, Tampa, Florida.

International journal of radiation oncology, biology, physics
|June 29, 2025
PubMed
概括

放射治疗 (RT) 通过改善瘤透淋巴细胞 (TIL) 扩张和T细胞透来增强采用细胞疗法 (ACT). 在临床前模型中,将RT与ACT结合起来显著提高了抗瘤活性,并完成了瘤回归.

更多相关视频

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

相关实验视频

Last Updated: Sep 17, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.1K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 辐射瘤学 辐射瘤学

背景情况:

  • 放射治疗 (RT) 和采用细胞治疗 (ACT) 的结合用于癌症治疗是新兴的研究领域.
  • 对于RT增强ACT的潜力,特别是瘤透性淋巴细胞 (TILs) 的潜力,仍未得到充分研究.

研究的目的:

  • 在人类乳头瘤病毒 (HPV) 阳性头角状细胞癌 (HNSCC) 的小鼠模型中评估将RT与ACT结合的疗效.
  • 调查RT在两个关键时间点:瘤前切除和ACT当天的施用RT的影响.

主要方法:

  • 在小鼠HNSCC模型中,在瘤切除5天前给药一次剂量RT (8 Gy).
  • 进行RNA测序以分析RT后的化学因表达.
  • 扩大了TILs,使用互白素-2 (IL-2) 实体检测,并评估了它们的反应性.
  • 使用RT治疗或未治疗瘤的TIL进行ACT,并评估T细胞透和抗瘤活性.

主要成果:

  • RT预条件显著增强了体外TIL扩张 (96%对74%) 和增加了TNF-α的产生,表明反应性有所改善.
  • RT增加了多功能细胞毒性CD8+TIL和上调的化学激素的扩张,支持增强的TIL招募.
  • 从RT预先条件的瘤中获得TIL的ACT导致优异的瘤控制,50%的瘤完全回归,而对照组的12.5%.
  • 与单独使用ACT或RT相比,在ACT当天的RT改善了T细胞透和瘤排斥.

结论:

  • 在瘤切除前应用的RT可增强TIL扩张和反应性.
  • 在ACT的当天服用RT可增加T细胞透和抗瘤功效.
  • 在这些不同的时间点将RT与ACT结合起来,显著改善治疗结果,显示出转移性疾病治疗的前景.